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Abstract
Background: Body composition is an important parameter for patients with chronic obstructive pulmonary disease (COPD)
whereas the association between asthma and obesity is not fully understood. The impact of severe refractory asthma (SRA)
on fat free mass (FFM) has not been investigated.
Methodology and Principal Findings: 213 subjects (70 healthy smokers, 71 COPD patients and 72 asthma patients) without
significant comorbidities were included in the study. In all patients, body composition assessment (using bioelectrical
impendance analysis, skinfold and anthropometric measurements) and spirometry were performed. Differences in fat free
mass index (FFMI) between groups were assessed and determinants of FFMI in asthma were evaluated. Patients with SRA
had lower values of FFMI compared to patients with mild-to-moderate asthma [18.0(17.3–18.3)–19.5(18.4–21.5), p,0.001],
despite the fact that they were more obese. The levels of FFMI in SRA were lower than those of GOLD stage I–III COPD and
comparable to those of stage IV COPD patients [18.0(17.3–18.3)–18.8(17.8–20.1), p=ns]. These differences were present
even after proper adjustments for sex, age, smoking status, daily dose of inhaled corticosteroids (ICS) and daily use of oral
corticosteroids (OCS). In multivariate analysis, independent predictors of FFMI in asthmatic patients were age, use of OCS
and the presence of SRA, but not smoking, sex or cumulative dose of ICS used.
Conclusions and Significance: SRA is related to the presence of low FFMI that is comparable to that of GOLD stage IV
COPD. The impact of this observation on asthma mechanisms and outcomes should be further investigated in large
prospective studies.
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Introduction
Body composition is an important parameter for humans as it
has been shown that either malnutrition or obesity, both expressed
as body mass index (BMI), are correlated with overall morbidity
and mortality [1]. Previous studies from the general population
indicate that high values of body fat (BF) and low values of fat free
mass (FFM) are independent predictors of all cause mortality [2].
Moreover, it was shown that in healthy subjects total BF, central
adiposity and FFM are associated with lung function [3], whereas
central adiposity seems to be a better predictor of lung function
compared to body weight or BMI [4]. Finally, an 8-year study in
the general population has shown that loss of weight and decrease
in BMI is associated with an increase in lung function [5].
Body composition represents a risk factor for the development of
both chronic obstructive pulmonary disease (COPD) and asthma
[6,7]. Men with low values of BMI are at increased risk for the
development of COPD [8]. Moreover, although it is unclear if
malnutrition is an independent risk factor for COPD development,
malnutrition and weight loss can reduce respiratory muscle mass and
the strength of the remaining muscle fibers [6]. On the contrary,
obesity represents a risk factor for asthma development [7]. It has
been shown that increase in BMI values predisposes to a new asthma
diagnosis in female young adults [9], and high values of BMI increase
the odds of incident asthma in both men and women [10].
On the other hand, smoking, COPD and asthma affect body
composition. There is evidence that smoking induces loss of body
weight, whereas smoking cessation provokes weight gain. More-
over, smoking contributes in the accumulation of visceral fat and
in the development of insulin resistance, metabolic syndrome and
type 2 diabetes [11]. Additionally, BMI and fat free mass index
(FFMI) are predictors of mortality in patients with COPD [12] and
lower values of BMI and FFMI are associated with increased risk
of death in patients with COPD [13,14]. In patients with asthma,
weight and BMI are associated with asthma control, and
overweight asthma patients are more difficult to achieve control
[15]. Several hypotheses have been raised for the understanding of
the association between asthma and obesity, including mechanical
impairment, the presence of comorbidities and systemic inflam-
mation and the role of adipose tissue hormones [16]. In contrast to
COPD patients, body composition, and especially FFM, has not
been extensively evaluated in patients with asthma.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13233The aim of the present study was to assess body composition in
patients with asthma and compare it to COPD patients and
healthy smokers. We tested the hypothesis that patients with severe
refractory asthma (SRA) might have lower FFMI than those with
mild-to-moderate asthma. Predictors of FFMI in patients with
asthma were further evaluated.
Materials and Methods
Study design
Study participants were asthmatic patients, COPD patients and
healthy smokers, without significant comorbidities that might
affect body composition, including history of cardiovascular
disease (CVD), diabetes mellitus, history of cancer, other lung
disease or any other chronic systemic disease. COPD and asthma
patients were recruited from the outpatients clinics of a tertiary
hospital and had stable disease for the previous 8 weeks. Diagnosis
of COPD and asthma has set at least one year before the inclusion
in the study by an expert respiratory physician (K.K.) with specific
interest in COPD and asthma, according to the existing guidelines
[6,7]. Healthy smokers were divided to current and ex smokers
(stopped smoking for at least one year prior to their inclusion).
A structured questionnaire was completed for all study
participants, including demographic data, as well as data
regarding their disease (for asthmatic and COPD patients) e.g.
duration of treatment, use of inhaled corticosteroids (ICS), total
ICS dose per day expressed in equivalent mcg of beclomethasone,
number of exacerbations during the past year which were treated
with short courses of oral corticosteroids (OCS), and daily dose of
OCS for some patients with SRA.
All subjects additionally completed a food frequency question-
naire (FFQ), which has been used in the Greek population, for the
assessment of their nutritional status [17,18]. All subjects were
submitted to body composition assessment, skinfolds measure-
ments, assessment of anthropometric parameters and simple
spirometry. The study protocol was approved by the review
board of the University Hospital of Larissa and all patients
provided written informed consent.
Body composition, skinfold and anthropometric
measurements
Body composition was assessed by bioelectrical impendance
analysis (BIA), with a commercially available body analyzer (BIA
101 System Analyser, Akern, Florence, Italy) according to current
recommendations [19,20]. FFMI was calculated as FFM/height
squared. Skinfolds were measured using a commercially available
calliper (GIMA, Plicometro skinfold calliper mechanical, San
Donato Milanese, Italy). Skinfolds measured were: biceps, triceps,
chest, subscapular, midaxillary, abdominal, suprailiac, thigh and
calf skinfold. Anthropometric circumferences and diameters were
measured using a commercially available measuring tape.
Measurements included the following parameters: neck circum-
ference, chest circumference, waist circumference, abdominal
circumference at the umbilicus level, circumference anteriorly
between the xiphoid process of the sternum and the umbilicus and
laterally between the lower end of the rib cage and iliac crests, iliac
circumference, iliac diameter, hip circumference and knee
circumference. All body composition measurements were per-
formed by the same experienced technician who was blinded to
the status of the study participants
Spirometry
All patients were submitted to spirometry by the same
experienced technician, using a commercially available system
(Master Screen, Erich Jaeger GmbH, Wuerzburg, Germany)
according to American thoracic society (ATS) guidelines [21].
Post-bronchodilator values were recorded for patients with asthma
and COPD.
Classification of Patients with Asthma and COPD
Patients with asthma were classified as mild-to-moderate asthma
patients and patients with SRA according to the ATS and global
initiative for asthma (GINA) guidelines [7,22,23]. COPD patients
were distributed to the stages of the disease according to their
forced expiratory volume in the 1
st second (FEV1), as it is referred
in the global initiative for chronic obstructive pulmonary disease
(GOLD) guidelines (Stage I – mild COPD FEV1$80.0%
predicted; Stage II – moderate COPD 50.0%#FEV1,80.0%
predicted; Stage III – severe COPD 30.0%#FEV1,50.0%; Stage
IV – very severe COPD FEV1#30.0% or FEV1,50.0% predicted
with respiratory failure) [6].
Statistical analysis
Normally distributed data are presented as mean6SD whereas
skewed data are presented as median (interquartile range).
Normality of distribution of the variables was assessed using the
D’Agostino-Pearson normality test. Comparisons of variables
between two groups was performed using unpaired Student’s t-
tests or Mann-Whitney U tests for normally distributed and
skewed variables, respectively whereas comparisons of variables
between three or more groups was performed using one way
ANOVA or Kruskal Wallis test for normally distributed and
skewed variables, respectively, with suitable post hoc analyses
(Bonferroni or Dunn’s, respectively) for all pairs of data. For the
comparison of FFMI among all groups of subjects a univariate
general linear model with appropriate adjustment for confounding
factors (sex, age, smoking habit, ICS dose and daily use of OCS)
was used; the equality of variances was assessed with Levere’s test
and post hoc analysis was performed with Dunnett’s T3 test.
Pearson and Spearman’s rank correlation coefficients were used
for the correlation between normally distributed and skewed
variables, respectively. Multiple regression analysis was performed
for the evaluation of FFMI predictors, using FFMI as dependent
variable and sex, age, smoking habit, cumulative ICS dose, daily
use of OCS and asthma classification (mild-to-moderate vs. SRA)
as independent variables. Stepwise multiple regression analysis
was additionally used for the development of a prediction equation
for FFM in patients with asthma, using anthropometric param-
eters. P values,0.05 were considered statistically significant.
Analyses were performed using GraphPad Prism 5 (GraphPad
Software Inc, La Jolla, CA, USA) and SPSS 16 (SPSS, Chicago,
IL, USA).
Results
In total, 213 patients were included in the study. Of these 70
were healthy smokers, 71 were COPD patients and 72 were
asthma patients. Demographic data for each group are presented
in Table 1. Smokers and COPD patients were mainly males,
whereas the asthma group was composed mainly by females.
Patients with asthma had higher values of BMI, fat mass (FM) and
fat mass index (FMI) (Table 1). All asthma patients were receiving
ICS compared to the 47.9% of COPD patients. Moreover, 9
(12.5%) patients with asthma were receiving OCS daily, all with
SRA. Table 2 shows the nutritional status of each group as it was
assessed with a FFQ and suggests that subjects in the three groups
had similar nutritional status and were not malnourished.
Body Composition in Asthma
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Regarding the group of healthy smokers, ex smokers had higher
values of body weight, BMI and FFMI compared to current
smokers (Table 3). Patients with stage IV COPD had lower values
of FFM and FFMI compared to the earlier stages of the disease,
whereas the values of FM and FMI were similar in all stages of the
disease (Table 4). Regarding asthma patients, patients with SRA
had higher values of BMI, FM and FMI and lower values of FFMI
(Table 5).
Differences in FFMI in all subgroups of healthy smokers,
COPD and asthma patients are presented in Figure 1. Patients
with SRA had significantly lower FFMI compared to healthy
current and ex smokers, as well as to patients with COPD stage I,
II, III and patients with mild-to-moderate asthma, whereas their
levels were comparable to those of stage IV COPD.
After proper adjustments for sex, age, smoking habit, ICS dose
and daily use of OCS, patients with SRA still presented
significantly lower FFMI compared to healthy current (p,0.001)
and ex smokers (p,0.001), as well as to patients with COPD stage
I (p=0.007), II (p,0.001), III (p=0.005), and patients with mild-
to-moderate asthma (p=0.002). Again, there was no difference
between patients with SRA and COPD stage IV (p=0.826).
Moreover, after the adjustments, ex smokers differed significantly
with COPD stage III (p=0.02), whereas there was no statistically
significant difference between COPD stage I and patients with
Table 1. Demographic data of the three groups of study participants.
Smokers COPD Asthma
(n=70) (n=71) (n=72)
Male/Female 58/12 49/22 18/54
Age (years) 56 (49–69) 70 (65–77) 61.5 (51–73.5)
Smoking status
Current smokers 48 (68.6%) 26 (36.6%) 3 (4.2%)
Ex smokers 22 (31.4%) 45 (63.4%) 3 (4.2%)
Non smokers 0 0 66 (91.6%)
PYS 40 (22–60) 65 (50–90) 30 (20–40)
ICS - 34 (47.9%) 72 (100%)
ICS dose (mcg) - 1000 (1000–2000) 1000 (1000–2000)
Daily OCS (n) - - 9
Courses of OCS during the past year - 19 (26.8%) 17 (23.6%)
FEV1 (%) 97.7611.8 57.168.6 88.0618.7
FVC (%) 98.1612.5 76.0619.0 93.6616.7
FEV1/FVC (%) 79.464.9 57.7611.3 74.3611.8
PEF (%) 89.6619.6 57.7620.6 75.6620.2
FEF25–75 (%) 85.6625.7 28.1614.9 59.4632.6
BW (kg) 85.0 (75.0–92.0) 79.0 (70.0–90.0) 86.5 (75.0–98.5)
BMI (kg/m
2) 28.5 (26.5–31.1) 27.0 (25.2–30.9) 33.2 (29.1–36.3)
FM (kg) 19.2 (16.8–22.3) 18.5 (12.7–23.8) 36.2 (23.3–47.9)
FMI (kg/m
2) 6.7 (5.4–7.8) 6.5 (4.6–8.2) 14.8 (8.8–17.8)
FFM (kg) 65.3 (61.1–72.0) 58.1 (54.1–67.4) 48.5 (44.3–57.8)
FFMI (kg/m
2) 22.1 (20.3–23.5) 20.7 (19.0–23.7) 18.8 (17.9–20.7)
Values are reported as mean 6 SD or median (interquartile ranges) for normally distributed and skewed data, respectively.
PYS: Pack Years, ICS: Inhaled corticosteroids, OCS: Oral corticosteroids, BW: Body Weight, BMI: Body Mass Index, FM: Fat Mass, FMI: Fat Mass Index, FFM: Fat Free Mass,
FFMI: Fat Free Mass Index, FEV1: Forced Expiratory Volume in the 1
st second, FVC: Forced Vital Capacity, PEF: Peak Expiratory Flow, FEF25–75: Forced mid-Expiratory Flow.
doi:10.1371/journal.pone.0013233.t001
Table 2. Food items consumed (in servings/week) in each
group.
Smokers COPD Asthma p-value
Red meat 1 (1–2) 1 (1–2) 1 (0–2) 0.856
Pork 1 (1–2) 1 (0–2) 1 (0–2) 0.394
Poultry 1 (1–2) 1 (1–2) 1 (0–2) 0.056
Fish 1 (1–2) 1 (1–2) 1 (1–2) 0.503
Egg 1 (1–3) 1 (0–2) 1 (0–2) 0.128
Bread and cereals 7 (3–7) 7 (5–7) 7 (6–7) 0.108
Pasta and rice 2 (1–3) 2 (1–3) 3 (1–4) 0.677
Potatoes 2 (2–3) 2 (1–3) 3 (1–3) 0.338
Vegetables 7 (4.5–7) 7 (4.5–7) 7 (5–7) 0.575
Fruit and juices 6 (4–7) 5 (3–7) 5 (4–7) 0.999
Milk and products full fat 2 (0–4.5) 5 (0–7) 5 (0–7) 0.213
Milk and products low fat 0 (0–0) 0 (0–0) 0 (0–0) 0.474
Cheese yellow 1 (0–4) 0 (0–2) 0 (0–3) 0.079
Cheese white 6 (4–7) 4.5 (3–7) 5 (4–7) 0.150
Legumes 5 (3–5.5) 4 (2–5) 5 (3–6) 0.269
Desert or ice cream 1 (0–3) 1 (0–2) 2 (1–3) 0.157
Values are reported as median (interquartile ranges).
doi:10.1371/journal.pone.0013233.t002
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presented in Figure 1 remained statistically significant.
Predictors of FFMI in Patients with Asthma
Predictors of FFMI in patients with asthma, provided by
multiple regression analysis, are presented in Table 6. Age, daily
use of OCS and the presence of SRA, but not sex, smoking habit
or the cumulative dose of ICS, were independent predictors of
FFMI (R
2: 0.960, Adjusted R
2: 0.956).
FFMI in patients with asthma was correlated with subscapular
skinfold (r=0.354, p=0.004), midaxillary skinfold (r=0.335,
p=0.007), neck circumference (r=0.268, p=0.039), waist circum-
ference (r=0.417, p=0.001), iliac diameter (r=0.411, p=0.002)
and knee circumference (r=0.314, p=0.025). Stepwise multiple
regression analysis using anthropometric parameters as indepen-
dent variables showed that FFM values can be predicted based on
weight, height, abdominal and calf skinfold and iliac diameter
(Unadjusted R
2: 0.999, Adjusted R
2: 0.998; Table 7).
Discussion
The results of the current study indicate that there are
differences in body composition among specific groups of healthy
smokers, COPD and asthma patients without comorbidities.
Patients with SRA have lower values of FFMI compared to
patients with mild-to-moderate asthma, despite the presence of
higher values of BMI and FMI. Additionally, the levels of FFMI in
SRA were lower than those of current and ex smokers and
comparable to those with stage IV COPD. Finally, age, daily use
of OCS and the presence of SRA were the only independent
predictors of FFMI in patients with asthma.
This is the first study to show that patients with SRA, despite the
fact that they are often obese, have also reduced values of FFMI.
Moreover, it was shown that SRA is an independent predictor of
FFMI in asthma patients. These patients had similar values of
FFMI compared to patients with stage IV COPD, although they
had higher values of BMI. Shore has recently proposed several
mechanisms which may interfere in the association between
obesity and asthma, such us mechanical factors, systemic
inflammation and the role of comorbidities [16]. On the other
hand it is known that patients with SRA present chronic airway
inflammation, with a possible activation of neutrophils [22]. It is
additionally known that obesity provokes systemic inflammation,
leading to the development of metabolic syndrome, insulin
resistance and high levels of CRP [24]. The coexistence of intense
local and systemic inflammation in these patients may lead to loss
of FFM in patients with SRA.
The fact that the presence of SRA was an independent
predictor of FFMI in asthmatics further supports the significance
of body composition assessment in that population. The results of
our study indicate that in patients with SRA, FFMI was also
associated with the use of OCS, whereas there was no association
with daily ICS dose. In a similar study by Targowski et al., it was
shown that systemic corticosteroids lead to loss of FFM in the
Table 3. Body composition in ex and current healthy
smokers.
Ex smokers
(n=22)
Current smokers
(n=48) p-value
BW (kg) 90.0 (80.0–92.0) 83.0 (71.3–89.3) 0.038
BMI (kg/m
2) 31.1 (27.5–33.8) 27.3 (26.1–29.8) 0.003
FM (kg) 20.4 (17.2–23.2) 19.1 (15.8–21.7) 0.235
FMI (kg/m
2) 6.9 (5.8–8.0) 6.5 (5.0–7.6) 0.194
FFM (kg) 68.0 (62.7–75.8) 65.0 (59.4–71.8) 0.143
FFMI (kg/m
2) 23.5 (21.7–26.9) 21.7 (20.0–23.0) 0.008
Values are reported as median (interquartile ranges).
BW: Body Weight, BMI: Body Mass Index, FM: Fat Mass, FMI: Fat Mass Index,
FFM: Fat Free Mass, FFMI: Fat Free Mass Index.
doi:10.1371/journal.pone.0013233.t003
Table 4. Body composition in COPD patients according to GOLD stages of the disease.
Stage I Stage II Stage III Stage IV p-value
(n=9) (n=32) (n=19) (n=11)
BW (kg) 92.0 (78.0–105.0) 79.0 (70.0–89.3) 75.0 (66.0–80.0) 76.0 (67.0–83.0) 0.073
BMI (kg/m
2) 30.9 (26.8–34.3) 27.0 (25.2–30.3) 26.0 (24.8–29.4) 26.6 (23.4–28.9) 0.179
FM (kg) 18.1 (12.4–22.8) 18.3 (13.2–22.8) 16.1 (11.2–23.3) 24.0 (12.5–26.9) 0.619
FMI (kg/m
2) 6.2 (4.4–7.3) 6.4 (4.8–8.1) 5.7 (4.1–9.2) 8.2 (4.4–9.4) 0.586
FFM (kg) 74.6 (63.8–79.7) 58.5 (54.6–67.8)‘ 57.1 (53.6–62.9)‘ 55.1 (48.8–57.7)‘ 0.002
FFMI (kg/m
2) 24.4 (22.1–26.9) 20.8 (19.4–23.8) 20.6 (19.3–22.8) 18.8 (17.8–20.1)‘ 0.004
Values are reported as median (interquartile ranges).
BW: Body Weight, BMI: Body Mass Index, FM: Fat Mass, FMI: Fat Mass Index, FFM: Fat Free Mass, FFMI: Fat Free Mass Index.
‘ Indicate statistically significant difference with Stage I.
doi:10.1371/journal.pone.0013233.t004
Table 5. Body composition in asthma patients according to
their stage of the disease.
Mild to moderate Severe refractory asthma p-value
(n=48) (n=24)
BW (kg) 83.0 (69.3–89.5) 97.0 (87.0–103.8) ,0.001
BMI (kg/m
2) 31.2 (27.3–34.0) 35.0 (34.6–37.4) ,0.001
FM (kg) 26.1 (22.3–37.4) 48.3 (41.7–54.3) ,0.001
FMI (kg/m
2) 9.7 (7.6–14.9) 17.3 (16.8–19.4) ,0.001
FFM (kg) 49.9 (43.1–65.6) 48.2 (44.7–49.5) 0.199
FFMI (kg/m
2) 19.5 (18.4–21.5) 18.0 (17.3–18.3) ,0.001
Values are reported as median (interquartile ranges).
BW: Body Weight, BMI: Body Mass Index, FM: Fat Mass, FMI: Fat Mass Index,
FFM: Fat Free Mass, FFMI: Fat Free Mass Index.
doi:10.1371/journal.pone.0013233.t005
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further support the role of OCS, but not of ICS, on body
composition of asthmatic patients, besides the role of age and the
presence of severe disease.
On the other hand, body composition has been widely studied
in COPD and the extrapulmonary effects of this disorder that
leads to cachexia and loss of FFM have been well established [6].
Our data replicate the findings of Ischaki et al. showing lower
FFMI in COPD patients with stage IV COPD compared to those
with stages 0 and I of the disease [26], since in the present study
patients at stage III and IV had lower values of FFMI compared to
patients at stage I of the disease. Regarding the loss of FFM in
COPD patients, several hypotheses have been suggested which
imply that COPD affects both structure and function of skeletal
muscles [27]. These effects of the disease in skeletal muscle mass
are very important, as it has been shown that FFM is an
independent predictor of mortality, irrespective of FM [28].
However, there are data implying that the loss of FFMI may be
attributed in dietary problems in COPD patients [29]. The results
of the current study, however, indicate that patients with severe
and very severe COPD have lower values of FFMI compared to
patients with milder disease, despite the fact that our COPD
patients had similar nutritional status compared to healthy
smokers and asthma patients.
We have additionally shown that anthropometric and skinfolds
methods may be used for the estimation of FFM in patients with
asthma. Despite the fact that there were no strong correlations
between single skinfolds and/or circumferences, we have shown
that a combination of them may be used for the estimation of FFM
in these patients. Equations using combinations of skinfold and/or
anthropometric parameters have been used for body composition
assessment in specific populations [30,31]. In a previous study,
Peterson et al. have developed equations using skinfold measure-
ments for the prediction of per cent BF (%BF) with a 4
compartment model [32]. In healthy subjects weight to height
ratio was the best predictor of BF [33], whereas in COPD patients,
anthropometry has been studied for the estimation of body
composition [34,35]. To the best of our knowledge, this is the first
study to assess body composition using skinfolds and anthropo-
metric parameters in patients with asthma, and the equation
provided from this study needs to be further validated in an
independent population.
However, although the strength of the study is the careful
selection of patients without comorbidities, this study has
limitations. A significant limitation is that there were differences
between the three groups concerning age, smoking status and
gender distribution. In the healthy smokers and COPD groups
subjects were predominantly male, whereas the asthmatics were
predominantly female. Moreover COPD patients were older
compared to asthma patients and healthy smokers. However, these
differences are attributed to the prevalence of the diseases in the
two genders, since it is known that SRA is more prevalent in
women whereas, in Greece, smokers and COPD patients are
mainly male [22,36]. Another possible limitation of our study is
the high prevalence of obesity and overweight in our population.
However, the prevalence of obesity in the Greek population is one
of the highest among Europe countries in both adults and children
[37]. In Thessaly, the area of origin of the population of the
present study, the overall prevalence of obesity was 26.6% whereas
the prevalence of overweight was 39.4% and the mean value of
BMI in that study was 27.5 kg/m
2 [38]. Therefore, our study
population is rather representative of the general population of the
area of Thessaly in terms of obesity. Moreover, the fact that the
significant differences of FFMI in all groups remained after the
additional analysis with proper adjustments for the aforemen-
tioned confounders, further supports the need for evaluation of
body composition in patients with SRA.
Figure 1. Comparison of FFMI between all subgroups of
subjects. ES: Ex smokers, CS: Current smokers, MtM: Mild-to-moderate
asthma, SRA: Severe refractory asthma.
doi:10.1371/journal.pone.0013233.g001
Table 6. Parameters associated with FFMI in asthma patients.
B* SE Beta
# 95% CI for B p-value
Sex 1.219 1.606 0.030 21.997, 4.425 0.451
Age 0.223 0.026 0.696 0.171, 0.275 ,0.001
Smoking 1.996 1.856 0.038 21.721, 5.714 0.287
ICS dose 0.000 0.001 20.034 20.003, 0.002 0.698
Daily OCS 24.548 1.691 20.088 27.935, 1.162 0.009
Stage
a 4.566 1.304 0.341 1.955, 7.177 0.001
*Unstandardized coefficients, SE: Standard error,
#Standardized coefficients.
ICS: Inhaled corticosteroids, OCS: Oral corticosteroids, Stage
a: mild to moderate
asthma or SRA.
doi:10.1371/journal.pone.0013233.t006
Table 7. Prediction equations for FFM in asthma patients.
B* SE Beta
# 95% CI for B p-value
Weight (kg) 0.275 0.045 0.519 0.171, 0.379 ,0.001
Height (cm) 0.176 0.026 0.575 0.116, 0.236 ,0.001
Skinfolds (cm)
Abdominal 0.327 0.030 0.278 0.258, 0.397 ,0.001
Calf 20.265 0.097 20.102 20.489, 20.042 0.026
Anthropometry (cm)
Iliac diameter 20.266 0..075 20.258 20.440, 20.093 0.008
*Unstandardized coefficients, SE: Standard error,
#Standardized coefficients.
doi:10.1371/journal.pone.0013233.t007
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the estimation of FFM. It has been proposed that in COPD
patients the method of choice for body composition assessment
should be dual energy X ray absorptiometry (DEXA) [39],
although in a previous study it was shown that DEXA did not
differ from anthropometric measurements in COPD patients, and
DEXA did not differ with either anthropometric or BIA
measurements in healthy subjects [40]. In another study, Lerario
et al. showed that both BIA and anthropometry presented good
reliability and correlation with DEXA in COPD patients [34].
Despite the wide evaluation of those methods in COPD patients
and healthy controls, there are no data in asthmatics, and further
studies validating our results using DEXA are warranted.
In conclusion, in the present study we have shown that in a
population of healthy smokers and patients with COPD and
asthma without comorbidities, SRA is related to the presence of
decreased FFMI that is comparable to that of GOLD stage IV
COPD. The impact of this observation on asthma outcomes
should be further investigated in large prospective studies.
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